1. Pink Sheet

Could Makary Face Facility Issues As US FDA Commissioner?

 
• By Sue Sutter, Derrick Gingery, and Nancy Pham

The Department of Government Efficiency cancelled leases for FDA office and lab space at numerous sites outside the Washington, DC, area, while many buildings on the agency’s White Oak, MD, campus were included on the General Services Administration’s initial list of “non-core” government properties for disposal.

Footprint in sand
The FDA's real property footprint could shrink under the second Trump Administration. (Shutterstock)
Key Takeaways
  • DOGE has cancelled 30 FDA leases outside the DC area, although the largest of those, a drug safety testing lab in St. Louis, reportedly has been reversed.
  • GSA’s initial list of “non-core” federal properties for disposal included the majority of buildings on FDA’s White Oak campus.
  • The agency’s shrinking real property footprint comes despite the return of FDA staff to in-person office work.

Martin Makary could quickly face facilities challenges if he is confirmed as the next commissioner of

The Department of Government Efficiency (DOGE) has cancelled leases for FDA office and lab space at numerous sites outside

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

US FDA COVID-19 Booster Strategy May Not Be As Controversial As It Seems

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s call for placebo-controlled trials to confirm the efficacy of COVID-19 boosters is drawing a lot of criticism, but former Commissioner Robert Califf also supported the idea.

US FDA Legislative Lead Calls For User Fee Reforms As Renewal Talks Near

 
• By Sarah Karlin-Smith

Deputy FDA Commissioner Grace Graham acknowledged the importance of user fees, while also calling for restructuring. She also said part of MAHA's mission is to reexamine uses of drugs not supported by data.

Califf In Conversation: ‘Decimated’ US FDA Teams Endanger Innovation

 
• By Barnaby Pickering

Pink Sheet sister publication In Vivo spoke to the former FDA commissioner about the recent layoffs and their impact on vaccine and other product development.

US FDA Vaccine Framework Coming In Weeks, But Details Vague

 
• By Sarah Karlin-Smith

New CBER Director Prasad will "unleash a massive" framework on vaccines, FDA Commissioner Marty Makary said 15 May, raising questions about the impact on products nearing approval.

More from Geography

US FDA COVID-19 Booster Strategy May Not Be As Controversial As It Seems

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s call for placebo-controlled trials to confirm the efficacy of COVID-19 boosters is drawing a lot of criticism, but former Commissioner Robert Califf also supported the idea.

EU Moment Of Truth For Obe-Cel And 10 Other New Medicines

 
• By Neena Brizmohun

Autolus’s CAR T therapy obe-cel is among the medicines that are this week due for an opinion by the European Medicines Agency on whether they should be marketed in the EU.

Blenrep’s Revival Gains Steam: EMA Decision Imminent As Japan Approves New Regimen

 
• By Neena Brizmohun

The European Medicines Agency is due to decide whether GSK’s previously approved multiple myeloma drug that was withdrawn from the market in 2022 should be approved again for use in combination with BorDex or PomDex. Meanwhile, Japan today became the second major regulator to approve the Blenrep combinations.